The grading of gliomas based on histological features has been a subject of debate for several decades. A consensus has not yet been reached because of technical limitations and inter-observer variations. While the traditional grading system has failed to stratify the risk of IDH-mutant astrocytoma, canonical histological and proliferative markers may be applicable to the risk stratification of IDH-wild-type astrocytoma. Numerous studies have examined molecular markers in order to obtain more clinically relevant information that will improve the risk stratification of gliomas. The CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, were identified as independent molecular markers of the worst clinical outcomes. Therefore, the 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System adopted these molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, respectively, as a grading system within tumor types. Of note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical of pediatric-type gliomas may demonstrate a relatively indolent clinical course, suggesting the existence of lower-grade adult IDH-wild-type astrocytoma. In terms of oligodendroglioma, IDH-mutant, and 1p/19q codeleted, consistent makers that predict poor outcomes have not yet been identified, and, thus, the current criteria have remained unchanged. Molecular testing to fulfill the revised WHO criteria is, however, not always available worldwide, and in that case, an integrated diagnosis combining all available complementary information is highly recommended. This review discusses controversial issues surrounding legacy grading systems and newly identified potential genetic markers of adult diffuse gliomas and provides perspectives on future grading systems.
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Louis, D. N., Ohgaki H., Wiestler O. D., Cavenee W. K. WHO Classification of Tumours of the Central Nervous System (International Agency for Research on Cancer, Lyon, 2016).
Komori, T. Updated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathology. Brain Tumor Pathol. 34, 139–140 (2017).
Akagi, Y. et al. Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification. Brain Tumor Pathol. 35, 81–89 (2018).
Ohba, S., Kuwahara, K., Yamada, S., Abe, M. & Hirose, Y. Correlation between IDH, ATRX, and TERT promoter mutations in glioma. Brain Tumor Pathol. 37, 33–40 (2020).
Komori, T. Updating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classification. Brain Tumor Pathol. 37, 1–4 (2020).
Louis, D. N. & von Deimling, A. Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zulch, the WHO… and Shakespeare. Acta Neuropathol. 134, 517–520 (2017).
WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours of the Central Nervous System (International Agency for Research on Cancer, Lyon, 2021) in press.
Wright, J. R. & Albert, C. Jr Broders’ paradigm shifts involving the prognostication and definition of cancer. Arch. Pathol. Lab. Med. 136, 1437–1446 (2012).
Etienne, D. et al. James Watson Kernohan (1896-198): frontiers in neuropathology. Clin. Anat. 25, 527–529 (2012).
Scheithauer, B. W. Development of the WHO classification of tumors of the central nervous system: a historical perspective. Brain Pathol. 19, 551–564 (2009).
Zülch, K. J. Histological Typing of Tumours of the Central Nervous System (World Health Organization, Geneva, 1979).
Kleihues, P., Burger, P. C., Scheithauer, B. W. Histological Typing of Tumours of the Central Nevous System (Springer-Verlag, Berlin, 1993).
Daumas-Duport, C., Scheithauer, B., O’Fallon, J. & Kelly, P. Grading of astrocytomas. A simple and reproducible method. Cancer 62, 2152–2165 (1988).
Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97–109 (2007).
Perry, A., Brat D. J. Practical Surgical Neuropathology (Elsevier, Philadelphia, 2018).
Takei, H., Bhattacharjee, M. B., Rivera, A., Dancer, Y. & Powell, S. Z. New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. Arch. Pathol. Lab. Med. 131, 234–241 (2007).
Habberstad, A. H., Gulati, S. & Torp, S. H. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas–an immunohistochemical study. Diagn. Pathol. 6, 43–51 (2011).
Suzuki, A. et al. Modified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumors. Brain Tumor Pathol. 34, 141–148 (2017).
Duregon, E. et al. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget 7, 2190–2198 (2016).
Kleihues, P., Cavenee, W. K. Pathology and Genetics of Tumors of the Nervous System (World Health Organization classification of tumors, IARC Press, Lyon, France, 2000).
Giannini, C. et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J. Neuropathol. Exp. Neurol. 58, 46–53 (1999).
Arima, N. et al. The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index. J. Clin. Pathol. 69, 255–259 (2016).
Louis, D. N. et al. Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol. 133, 1–3 (2017).
Louis, D. N. et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 30, 844–856 (2020).
Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008).
Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803–820 (2016).
Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl Acad. Sci. USA 110, 6021–6026 (2013).
Arita, H. et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol. Commun. 4, 79–93 (2016).
Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).
Eckel-Passow, J. E. et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N. Engl. J. Med. 372, 2499–2508 (2015).
Brat, D. J., Verhaak, R. G., Aldape, K. D., Yung, W. K. & Salama, S. R. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481–2498 (2015).
Olar, A. et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 129, 585–596 (2015).
Yoda, R. A. et al. Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma. J. Neuropathol. Exp. Neurol. 78, 1002–1010 (2019).
Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231–1251 (2021).
Yang, R. R. et al. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol. 30, 541–553 (2019).
Li, K. K. et al. Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. Neurooncol. Adv. 1, 1–11 (2019).
Korshunov, A. et al. Integrated molecular characterization of IDH-mutant glioblastomas. Neuropathol. Appl. Neurobiol. 45, 108–118 (2019).
Binder, H. et al. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development. Acta Neuropathol. Commun. 7, 59 (2019).
Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550–563 (2016).
Ferreyra Vega, S. et al. DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. Clin Epigenet. 13, 102–113 (2021).
Cimino, P. J. et al. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathol. Commun. 5, 39–53 (2017).
Cimino, P. J. & Holland, E. C. Targeted copy number analysis outperforms histological grading in predicting patient survival for WHO grade II/III IDH-mutant astrocytomas. Neuro Oncol. 21, 819–821 (2019).
Reis, G. F. et al. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J. Neuropathol. Exp. Neurol. 74, 442–452 (2015).
Shirahata, M. et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 136, 153–166 (2018).
Appay, R. et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 21, 1519–1528 (2019).
Aoki, K. et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 20, 66–77 (2018).
Phillips, J. J. et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 23, 565–573 (2013).
Weller, M., et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 129, 679–693 (2015)
Stichel, D. et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 136, 793–803 (2018).
Tesileanu, C. M. S. et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 22, 515–523 (2020).
Kuwahara, K. et al. Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosis. Brain Tumor Pathol. 36, 135–143 (2019).
Reuss, D. E. et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 130, 407–417 (2015).
Capper, D. et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 136, 181–210 (2018).
Richardson, T. E., Hatanpaa, K. J. & Walker, J. M. Molecular characterization of “True” low-grade IDH-wild-type astrocytomas. J. Neuropathol. Exp. Neurol. 80, 431–435 (2021).
Berzero, G. et al. IDH-wild-type lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol. 23, 955–966 (2021).
Giannini, C. & Giangaspero, F. TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma? Neuro Oncol. 23, 865–866 (2021).
Fujimoto, K. et al. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wild-type diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol. 142, 323–338 (2021).
Giannini, C. et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 18, 360–369 (2008).
Giannini, C. et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J. Neuropathol. Exp. Neurol. 60, 248–262 (2001).
Komori, T. et al. Controversies over the diagnosis of oligodendroglioma: a report from the satellite workshop at the 4th international symposium of brain tumor pathology, Nagoya Congress Center, May 23, 2012. Brain Tumor Pathol. 30, 253–261 (2013).
Halani, S. H. et al. Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis. Oncol. 2, 24–33 (2018).
Labreche, K. et al. TCF12 is mutated in anaplastic oligodendroglioma. Nat. Commun. 6, 7207–7216 (2015).
So, J., Mamatjan, Y., Zadeh, G., Aldape, K. & Moraes, F. Y. Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis. Neuro Oncol. 23, 795–802 (2021).
Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 22, iv1–iv96 (2020).
Tateishi, K., Nakamura, T. & Yamamoto, T. Molecular genetics and therapeutic targets of pediatric low-grade gliomas. Brain Tumor Pathol. 36, 74–83 (2019).
Komori, T. The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system. Brain Tumor Pathol. 38, 1–3 (2021).
Ellison, D. W. et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol. 30, 863–866 (2020).
Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
Wick, W. et al. MGMT testing–the challenges for biomarker-based glioma treatment. Nat. Rev. Neurol. 10, 372–385 (2014).
Friedman, H. S. et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol. 16, 3851–3857 (1998).
Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 13, 707–715 (2012).
Fukai, J. et al. Molecular characteristics and clinical outcomes of elderly patients with IDH-wild-type glioblastomas: comparative study of older and younger cases in Kansai Network cohort. Brain Tumor Pathol. 37, 50–59 (2020).
Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510–522 (2010).
Malta, T. M. et al. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro Oncol. 20, 608–620 (2018).
Aoki, K. & Natsume, A. Overview of DNA methylation in adult diffuse gliomas. Brain Tumor Pathol. 36, 84–91 (2019).
Woo, H. Y. et al. Glioblastomas harboring gene fusions detected by next-generation sequencing. Brain Tumor Pathol. 37, 136–144 (2020).
Ellison, D. W. et al. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol. 137, 683–687 (2019).
Cohen, A. et al. DNA copy number analysis of grade II–III and grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathol. Commun. 3, 34–46 (2015).
Mirchia, K. et al. Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas. Acta Neuropathol. Commun. 7, 121–124 (2019).
Adachi, J.-i et al. Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma. Brain Tumor Pathol. 38, 201–209 (2021).
Miki, S. et al. Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR. Brain Tumor Pathol. 37, 154–158 (2020).
Yokogami, K. et al. Impact of PCR-based molecular analysis in daily diagnosis for the patient with gliomas. Brain Tumor Pathol. 35, 141–147 (2018).
Louis, D. N. et al. Data sets for the reporting of tumors of the central nervous system: recommendations from the International Collaboration on Cancer Reporting. Arch. Pathol. Lab. Med. 144, 196–206 (2020).
Andreiuolo, F., Mazeraud, A., Chretien, F. & Pietsch, T. A global view on the availability of methods and information in the neuropathological diagnostics of CNS tumors: results of an international survey among neuropathological units. Brain Pathol. 26, 551–554 (2016).
Louis, D. N. et al. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 24, 429–435 (2014).
Sonoda, Y. et al. Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors. Brain Tumor Pathol. 36, 56–62 (2019).
Rajeswarie, R. T., Rao, S., Nandeesh, B. N., Yasha, T. C. & Santosh, V. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. J. Clin. Pathol. 71, 323–329 (2018).
Yamauchi, T. et al. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas. Brain Tumor Pathol. 35, 148–158 (2018).
Natsumeda, M., et al. Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. Brain Tumor Pathol. (2021)
Roux, A. et al. Prognostic relevance of adding MRI data to WHO 2016 and cIMPACT-NOW updates for diffuse astrocytic tumors in adults. Working toward the extended use of MRI data in integrated glioma diagnosis. Brain Pathol. 31, e12929 (2021).
Johnson, D. R. et al. Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI. Am. J. Neuroradiol. 38, 678–684 (2017).
Smits, M. Imaging of oligodendroglioma. Br. J. Radiol. 89, 20150857 (2016).
Latysheva, A. et al. Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach. Neuroradiology 61, 545–555 (2019).
Fellah, S. et al. Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? Am. J. Neuroradiol. 34, 1326–1333 (2013).
Chawla, S. et al. Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. Am. J. Neuroradiol. 34, 1542–1549 (2013).
Broen, M. P. G. et al. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol. 20, 1393–1399 (2018).
Jain, R. et al. “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol. 22, 936–943 (2020).
Saito, T. et al. Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas. Brain Tumor Pathol. 33, 175–182 (2016).
Ammendola, S., et al. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Virchows Arch. https://doi.org/10.1007/s00428-021-03134-1 (2021).
Filipski, K. et al. Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. Acta Neuropathol. 138, 331–334 (2019).
Yamamichi, A. et al. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. Brain Tumor Pathol. 35, 106–113 (2018).
Louis, D. N. et al. cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathol. 135, 481–484 (2018).
Louis, D. N. et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 135, 639–642 (2018).
Chapel, D. B. et al. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod. Pathol. 33, 245–254 (2020).
Satomi, K. et al. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Mod. Pathol. 34, 688–700 (2021).
Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469–474 (2018).
Cui, M. & Zhang, D. Y. Artificial intelligence and computational pathology. Lab Investig. 101, 412–422 (2021).
This manuscript is dedicated to my late mentor, Dr. Bernd W. Scheithauer from the Mayo Clinic.
The author declares no competing interests.
This review did not have any ethical issue.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Komori, T. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. Lab Invest (2021). https://doi.org/10.1038/s41374-021-00667-6